PAM
RVMD icon

Pamalican Asset Management’s Revolution Medicines RVMD Stock Holding History

Pamalican Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75,000
Closed -$3.28M – 31
2024
Q4 		$3.28M Buy
+75,000
New +$3.78M 1.45% 24

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pamalican Asset Management's RVMD Position: Q1 2025 in Review

Pamalican Asset Management sold out of Revolution Medicines (RVMD) in Q1 2025, closing a stake of 75,000 shares — an estimated $3.28M sold.

Pamalican Asset Management first reported a position in RVMD in Q4 2024 and held it in 1 quarter. The position peaked at $3.28M in Q4 2024. 284 funds tracked by Wall St. Rank hold RVMD as of Q1 2025.

  • Pamalican Asset Management reported no remaining Revolution Medicines position as of Q1 2025 after selling out during the quarter.
  • Pamalican Asset Management sold 75,000 Revolution Medicines shares in Q1 2025, an estimated $3.28M.
  • Pamalican Asset Management first reported a position in Revolution Medicines in Q4 2024 and held it in 1 quarter.
  • Pamalican Asset Management's Revolution Medicines position peaked at $3.28M in Q4 2024.
  • 284 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2025.

Based on Pamalican Asset Management's 13F filing for Q1 2025, filed 9 May 2025.